Trial Profile
A Phase 1 Study to Evaluate Safety and Tolerability of NKTR-214 (BMS-986321) Administered in Combination With Nivolumab (BMS-936558) in Advanced Malignant Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2022
Price :
$35
*
At a glance
- Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 22 Jan 2020 Status changed from recruiting to completed.
- 17 Jun 2019 Status changed from not yet recruiting to recruiting.
- 31 Jan 2019 Planned initiation date changed from 25 Jan 2019 to 8 Feb 2019.